Azacitidine and Enasidenib for IDH-2 Mutations

Targeted Therapy With the IDH2-Inhibitor Enasidenib (AG221) for High-Risk IDH2-Mutant Myelodysplastic Syndrome

More Information

Trial Status
Accepting patients
Trial Phase
Phase 2
Enrollment
63 patients (estimated)
Sponsors
MD Anderson Cancer Center
Collaborators
National Cancer Institute (NCI), Celgene Corporation, a wholly owned subsidiary of Bristol Myers Squibb
Tags
Antimetabolites, IDH2 Inhibitor
Trial Type
Treatment
Last Update
4 weeks ago
SparkCures ID
1555
NCT Identifier
NCT03383575

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print a patient-friendly report to share with your patient.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.